<DOC>
	<DOCNO>NCT00053131</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor filgrastim sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . It yet know whether combination chemotherapy effective follow filgrastim sargramostim treat leukemia . PURPOSE : Randomized phase II trial compare effectiveness combination chemotherapy follow filgrastim combination chemotherapy follow sargramostim treating patient relapse refractory acute myeloid leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Filgrastim Sargramostim Treating Patients With Relapsed Refractory Acute Myeloid Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare amount dendritic cell leukemia-associated antigen-specific T lymphocytes patient relapse refractory acute myeloid leukemia acute lymphoblastic leukemia treat filgrastim ( G-CSF ) v sargramostim ( GM-CSF ) high-dose cytarabine mitoxantrone . OUTLINE : This randomize study . All patient receive high-dose cytarabine IV 1 hour twice daily day 1-6 mitoxantrone IV 30 minute day 2-4 . On day 6 , patient randomize 1 2 treatment arm . - Arm I : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily blood count recover absence unacceptable toxicity . - Arm II : Patients receive sargramostim ( GM-CSF ) SC daily arm I . PROJECTED ACCRUAL : A total 60 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia acute lymphoblastic leukemia morphology , cytochemical staining , flow cytometry In first subsequent relapse refractory disease least 1 prior treatment regimen Antecedent hematologic disorder allow except Philadelphia chromosomepositive chronic myelogenous leukemia PATIENT CHARACTERISTICS : Age 15 Performance status 03 Life expectancy At least 4 week Hematopoietic Not specify Hepatic Bilirubin great 2 time normal* SGOT great 2 time normal* NOTE : *Unless directly attributable leukemia Renal Creatinine great 1.5 time normal* NOTE : *Unless directly attributable leukemia Cardiovascular Ejection fraction least 45 % * NOTE : *Unless directly attributable leukemia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent medical psychiatric illness would preclude study entry PRIOR CONCURRENT THERAPY : Biologic therapy Prior autologous allogeneic bone marrow peripheral blood stem cell transplantation allow Prior cytokine allow Chemotherapy Prior chemotherapy allow Endocrine therapy No concurrent corticosteroid except treatment severe vomit refractory standard agent Radiotherapy Prior radiotherapy allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>